Identification | Back Directory | [Name]
5'-O-(4,4'-Dimethoxytrityl)-N6-benzoyl-2'-deoxyadenosine-3'-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite | [CAS]
98796-53-3 | [Synonyms]
DMT-dA(bz) AMidite Bz-dA Phosphoramidite -deoxyadenosine-3' DMT-dA(bz) Pharmadite DA-CE PHOSPHORAMIDITE DNA A PHOSPHORAMIDITE DMT-dA-CEPhosphoramidite dA(N-Bz) Phosphoramidite DMT-Bz-dA phosphoramidite DMT-dA(bz) PhosphoraMidite 5'-DMT-Bz-dA phosphoramidite DMT-DA(BZ) AMIDITE 5G SINGLE DMT-dA(bz) Amidite, 5g, 6pack DMT-dA(Bz)-CE Phosphoramidite DMT-DA(BZ) AMIDITE 10G SINGLE DMT-dA(bz) Amidite 20g, 6 Pack DMT-dA(bz) Amidite 8.05g, 6 Pack 2'DEOXYADENOSINE PHOSPHORAMADITE REF DUPL: dA(bz) Phosphoramidite 2'-DEOXYADENOSINE PHOSPHORAMIDITE DMT-dA(bz) Amidite 2g, 89, 12 Pack DMT-dA(bz) Amidite 1g, 89, 12 Pack DMT-DA(BZ) AMIDITE 2G AB 12 PACK -Dimethoxytrityl)-N6-benzoyl-2' DMT-DA(BZ) AMIDITE 1G AB 12 PACK DMT-dA(bz) Amidite 2g, 60ml vial, 12 Pac DMT-DA(BZ) AMIDITE 4G 60ML VIAL 12 PAC DMT-dA(bz) Amidite 1g, 60ml vial, 12 Pac deoxyadenosine-ce phosphoramidite for cyclone -(2-cyanoethyl-N,N-diisopropyl)phosphoramidite N6-benzoyl-DMT-2'-deoxyadenosine-3'-CE Phosphoramidite 5'-O-DMT-N6-Benzyoyl-2'-Deoxy Adenosine Phosphoramidite N-blocked-5'-O-DMT 3'-CED deoxyadenosine phosphoramidite 5'-O-DMT-N6-Benzoyl-2'-deoxyadenosine 3'-CE phosphoramidite N6-Benzoyl-2'-deoxy-5'-O-DMT-cytidine 3'-CE Phosphoramidite N6-Benzoyl-5'-O-DMT-2'-deoxyadenosine-3'-CE Phosphoramidite N6-Benzoyl-2'-deoxy-3'-O-DMT-adenosine 5'-CE phosphoramidite N6-Benzoyl-2'-deoxy-5'-O-DMT-adenosine 3'-CE phosphoramidite 3'-O-P-5'-O-DMT-N-BZ-2'-DEOXY-ADENOSINE [DA(BZ) PHOSPHORAMIDITE] N6-Benzoyl-2'-deoxy-5'-O-DMT-adenosine 3'-CE phosphoraMidite N6-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyadenosine-3'-cyanoethyl Phosphoramidite N6-BENZOYL-5'-O-(DIMETHOXYTRITYL)-2'-DEOXYADENOSINE-3'-N,N-DIISOPROPYL (CYANOETHYL) PHOSPHORAMIDITE 5'-Dimethoxytrityl-N-benzoyl-2'-deoxyAdenosine,3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite 5'-O-(4,4'-DIMETHOXYTRITYL)-N6-BENZOYL-2'-DEOXYADENOSINE-3'-(2-CYANOETHYL-N,N-DIISOPROPYL)PHOSPHORAMIDITE N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine-3′-O-[O-(2-cyanoethyl)-N,N′-diisopropylphosphoramidite] 5'-O-(4,4'-Dimethoxytrityl)-N6-benzoyl-2'-deoxyadenosine-3'-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite USP/EP/BP N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-adenosine 3'-[2-cyanoethyl bis(1-methylethyl)phosphoramidite] Adenosine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-, 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] (2R,3S,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)tetrahydrofuran-3-yl 2-cyanoethyl diisopropylphosphoramidite | [EINECS(EC#)]
685-521-7 | [Molecular Formula]
C47H52N7O7P | [MDL Number]
MFCD00036314 | [MOL File]
98796-53-3.mol | [Molecular Weight]
857.93 |
Chemical Properties | Back Directory | [density ]
1.23 at 20℃ | [vapor pressure ]
0-0Pa at 20-50℃ | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
soluble, clear | [form ]
powder or granules | [pka]
7.87±0.43(Predicted) | [color ]
white to off-white | [biological source]
non-animal source (no BSE/TSE risk) | [Water Solubility ]
soluble, clear | [InChIKey]
GGDNKEQZFSTIMJ-AKWFTNRHSA-N | [SMILES]
O(C(C1=CC=C(OC)C=C1)(C1=CC=C(OC)C=C1)C1=CC=CC=C1)C[C@H]1O[C@@H](N2C3C(=C(N=CN=3)NC(=O)C3=CC=CC=C3)N=C2)C[C@@H]1OP(N(C(C)C)C(C)C)OCCC#N | [LogP]
7.14 at 20℃ |
Hazard Information | Back Directory | [General Description]
DMT-dA(bz) Phosphoramidite belongs to the group of DNA Phosphoramidites. Its key features include: Exocyclic amine functions are protected by a benzoyl group (dA(bz) anddC(bz)) or isobutyryl group (dG(ib)). Recommended cleavage and deprotection conditions are 8 hours at 55 °Cor 24 hours at room temperature using concentrated ammonia solution,for standard base-protected oligonucleotides. The high coupling efficiency of Proligo′s DNA phosphoramidites leads tohigh-yield and high-quality oligonucleotides.
| [Uses]
N6-Benzoyl-2’-deoxy-5’-O-DMT-cytidine 3’-CE Phosphoramidite is used to prepare antisense oligonucleotides containing conformationally constrained methoxyaminomethylene and aminooxymethylene and aminomethylene bridged nucleoside analogs. | [Synthesis]
Synthesis of (2R,3S,5R)-5-(6-benzoylamino-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide from N-(9-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- hydroxytetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide: The general procedure for synthesizing (2R,3S,5R)-5-(6-benzoylamino-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl) Methoxy)methyl)tetrahydrofuran-3-yl(2-cyanoethyl)diisopropylphosphoramidite was carried out in the following general steps: the nucleoside was phosphorylated using the N-methylimidazole salts of [O-β-cyanoethyl-N,N,N',N'-tetraisopropylphosphoramidite] and saccharin as the activators. This was done as follows: nucleoside (1.5 mmol) was added in a flask of appropriate size and the solid was dried by azeotropic distillation twice (using a rotary evaporator) with 20 mL of pyridine. After purging the flask with argon, 15 mL of acetonitrile was added. The mixture was stirred at room temperature until a clarified solution was formed. Subsequently, [O-β-cyanoethyl-N,N,N',N'-tetraisopropylphosphoramidite] (Tetraphos) was added to the solution, followed by the N-methylimidazole salt of saccharin. The reaction mixture was stirred continuously at room temperature and the progress of the reaction was monitored by HPLC. Upon completion of the reaction, the mixture was diluted with 30 mL of ethyl acetate and the organic phase was washed sequentially with 2 x 25 mL of saturated aqueous sodium bicarbonate and 25 mL of saturated aqueous sodium chloride. The organic layer was separated and dried with anhydrous magnesium sulfate. The dried suspension was filtered and the solvent was removed using a rotary evaporator. Finally, the residue was dried under vacuum to obtain the target product as a foamy solid. | [References]
[1] Patent: WO2004/35599, 2004, A1. Location in patent: Page 9-10 [2] Patent: WO2004/35599, 2004, A1. Location in patent: Page 10-11 |
|
|